首页> 外文期刊>Frontiers in Pharmacology >Activation of Nicotinic Acetylcholine α7 Receptor Attenuates Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Downregulating the NLRP3 Inflammasome
【24h】

Activation of Nicotinic Acetylcholine α7 Receptor Attenuates Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Downregulating the NLRP3 Inflammasome

机译:烟碱型乙酰胆碱α7受体的激活通过下调NLRP3炎性体来减轻大鼠中由久他茶碱引起的肺动脉高压的进展。

获取原文
           

摘要

Background: Inflammation and altered immunity contribute to the development of pulmonary arterial hypertension (PH). The alpha 7 nicotinic acetylcholine receptor (α7nAChR) possesses anti-inflammatory activities. The current study was performed to investigate the effects of a selective α7nAChR agonist, PNU-282987, on controlling a monocrotaline (MCT)-induced rat model of PH and explored the underlying mechanisms. Methods: Sprague-Dawley rats were injected with MCT and treated with PNU-282987 at the prevention (starting 1 week before MCT) and treatment (starting 2 weeks after MCT) settings. Four weeks after MCT injection, hemodynamic changes, right ventricular structure, and lung morphological features were assessed. Enzyme-linked immunosorbent assay, Western blot and q RT-PCR were performed to assess levels of inflammatory cytokines and NLRP3 (Nod-like receptor family pyrin domain-containing 3) inflammasome pathway in the rat lung tissues. In addition, the lung macrophage line NR8383 was used to confirm the in vivo data. Results: Monocrotaline injection produced PH in rats and downregulated α7nAChR mRNA and protein expression in rat lung tissues compared to sham controls. Pharmacological activation of α7nAChR by PNU-282987 therapy improved the rat survival rate, attenuated the development of PH as assessed by remodeling of pulmonary arterioles, reduced the right ventricular (RV) systolic pressure, and ameliorated the hypertrophy and fibrosis of the RV in rats with MCT-induced PH. The expression of TNF-α, IL-6, IL-1β, and IL-18 were downregulated in rat lung tissues, which implied that PNU-282987 therapy may help regulate inflammation. These protective effects involved the inhibition of the NLRP3 inflammasome. In vitro assays of cultured rat lung macrophages confirmed that the anti-inflammation effect of PNU-282987 therapy may contribute to the disturbance of NLRP3 inflammasome activation. Conclusion: Targeting α7nAChR with PNU-282987 could effectively prevent and treat PH with benefits for preventing ongoing inflammation in the lungs of rats with MCT-induced PH by inhibiting NLRP3 inflammasome activation.
机译:背景:炎症和免疫力改变导致肺动脉高压(PH)的发展。 α7烟碱乙酰胆碱受体(α7nAChR)具有抗炎活性。进行本研究以研究选择性α7nAChR激动剂PNU-282987对控制由一线crotacroline(MCT)诱导的大鼠PH的影响,并探讨了其潜在机制。方法:给Sprague-Dawley大鼠注射MCT,并在预防(MCT之前1周开始)和治疗(MCT之后2周开始)内使用PNU-282987进行治疗。注射MCT后四周,评估血流动力学变化,右心室结构和肺部形态特征。进行了酶联免疫吸附测定,Western印迹和q RT-PCR来评估大鼠肺组织中炎性细胞因子和NLRP3(含Nod样受体家族的吡啶结构域3)炎症小体途径的水平。另外,肺巨噬细胞系NR8383用于证实体内数据。结果:与假对照组相比,莫诺他林注射液在大鼠中产生PH,并在大鼠肺组织中下调α7nAChRmRNA和蛋白表达。 PNU-282987疗法通过药理学激活α7nAChR改善了大鼠的存活率,减轻了PH的发展(通过肺小动脉的重塑评估),降低了右心室(RV)的收缩压,并改善了RV大鼠的RV肥大和纤维化MCT诱导的PH。在大鼠肺组织中TNF-α,IL-6,IL-1β和IL-18的表达下调,这暗示PNU-282987治疗可能有助于调节炎症。这些保护作用涉及对NLRP3炎性体的抑制。培养的大鼠肺巨噬细胞的体外测定证实,PNU-282987治疗的抗炎作用可能有助于破坏NLRP3炎性体的活化。结论:以PNU-282987靶向α7nAChR可以有效预防和治疗PH,并通过抑制NLRP3炎性体活化来预防MCT诱导的PH大鼠肺部持续炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号